

Index to Volume Twenty

Index of Issues: January–February 1–60: March–April 61–120: May–June 121–180: July–August 181–242: September–October 243–300: November–December 301–360.

INDEX OF AUTHORS

- A**
- Abdullah AN, 344
 Addiss DG, 28
 Agacfidan A, 236
 Alain Brueat Physician Group, 51
 Albrecht KD, 140
 Almaraz A, 257
 Anderson JE, 201
 Anderson R, 168
 Anderson RM, 181
 Ashley RL, 239
 Ayowa OB, 96
- B**
- Baddour LM, 238
 Badur S, 236
 Baker C, 198
 Baker SA, 352
 Baker SL, 45
 Ballard RC, 5
 Bansal J, 220
 Barditch P, 346
 Barnes W, 279
 Bassa AGH, 164
 Bauer HM, 274
 Becker TM, 286
 Beebe JL, 140
 Benes S, 227
 Bergeron MG, 314
 Black JR, 262
 Bolan G, 14
 Botcherby M, 21
 Bottles K, 121
 Boyer R, 100
 Bradet R, 100
 Bramdev A, 164
 Bratos MA, 257
 Brinton LA, 279
 Brock S, 36
 Brown JE, 96
 Brown RC, 96
 Brunham RC, 168
 Bucquet D, 51
 Budd J, 89
- C**
- Cadell DM, 274
 Callahan JD, 220
 Castriciano S, 301
 Castro I, 314
 Cates W Jr, 174
- Cathrine V, 61
 Catoe KE, 77
 Catotti DN, 77
 Chamberland S, 314
 Cheang M, 168
 Chernesky MA, 152, 301
 Choong J, 248
 Clarke P, 77
 Cloud GA, 45
 Constantine NT, 220
 Copeland C, 279
 Corey L, 230
 Covino JM, 227, 262
 Cross E, 36
 Cuervo M, 257
 Cummings MC, 227, 262
- D**
- Dahlöf LG, 10
 Dalessio J, 230
 Dangor Y, 5
 Daniell FD, 294
 Danielsson D, 143
 Dan M, 158
 Darougar S, 61
 Davis CH, 248
 Davis JP, 28
 Debby A, 158
 de la Maza LM, 352
 DiGiorgio-Haag L, 307
 Dines RJ, 61
 Douglas JM Jr, 290
 Dowda H, 334
 Draft K, 227
 Dragavon J, 230
 Duval B, 100
- E**
- Eiros JM, 257
 Ekstrand M, 307
 Epp J, 279
 Ernst AA, 66
- F**
- Finelli L, 89
 Forslin L, 143
 Fortin C, 100
- G**
- Gamble WB Jr, 334
 Garnett G, 168
- Garnett GP, 105, 181
 Gee L, 307
 Gerikalmaz O, 236
 Gill MJ, 329
 Glass AG, 274
 Godin G, 100
 Gravitt P, 279
 Greer CE, 286
 Groves D, 152
 Gunn RA, 334
 Gutiérrez-Rodríguez MP, 257
 Gutmann J, 137
 Gutman R, 158
- H**
- Handsfield HH, 237, 269, 290
 Hanna N, 21
 Hart G, 126
 Hawkins RE, 294
 Hayes C, 36
 Hay PE, 1
 Heaton CG, 70
 Hearst N, 14
 Hildesheim A, 274, 279
 Hildeshiem A, 286
 Hillman RJ, 21
 Hilton JF, 307
 Hippeläinen M, 321
 Holmes KK, 41, 214, 230
 Hook EW III, 269
 Hoosen AA, 164, 265
 Hörting-Müller I, 243
 Hounsai A, 100
 Hunt WC, 286
 Hyams KC, 36, 294
- I**
- Ison C, 105
 Ison CA, 329
- J**
- Jang D, 152, 301
 Johansson E, 143
 Jones JL, 334
 Jones RB, 269
 Jones S, 279
 Joyce CF, 105
 Jutto P, 334
- K**
- Kallings I, 338
 Kamwendo F, 143
- Katz A, 158
 Kegeles SM, 14
 Keogh J, 307
 Kirby J, 118
 Knight ST, 248
 Kopp W, 243
 Koskela H, 321
 Koutsky LA, 230
 Krantz I, 10
 Krogwold RA, 36
 Kurman RJ, 274, 279
- L**
- Lampe M, 214
 Landers DV, 121
 Larroque B, 51
 Lee FK, 230
 Legault J, 198
 Lindan C, 14
 Lind I, 338
 Ludka D, 28
 Luger A, 110
 Luinstra K, 301
 Luinstra KE, 152
- M**
- Mahnès G, 100
 Mahoney MC, 209
 Mahony J, 301
 Mahony JB, 152
 Malone JD, 294
 Manos MM, 274, 279, 286
 Marsiglia VC, 220
 Martin DH, 66
 Martín-Rodríguez JF, 257
 McCormack WM, 227, 262, 269
 McCusker J, 81
 McKenzie P, 1
 McLaughlin CC, 209
 McMaster J, 168
 Meheus A, 194
 Mercer L, 137
 Messeri P, 70
 Messiah A, 51
 Mettetal J-F, 51
 Metzger BB, 209
 Meyer P, 334
 Michalek AM, 209
 Mogabgab WJ, 269
 Moi H, 143
 Moodley J, 164
 Morrison DM, 352

Index to Volume Twenty

Index of Issues: January–February 1–60: March–April 61–120: May–June 121–180: July–August 181–242: September–October 243–300: November–December 301–360.

INDEX OF AUTHORS

- A**
- Abdullah AN, 344
 Addiss DG, 28
 Agacfidan A, 236
 Alain Brueat Physician Group, 51
 Albrecht KD, 140
 Almaraz A, 257
 Anderson JE, 201
 Anderson R, 168
 Anderson RM, 181
 Ashley RL, 239
 Ayowa OB, 96
- B**
- Baddour LM, 238
 Badur S, 236
 Baker C, 198
 Baker SA, 352
 Baker SL, 45
 Ballard RC, 5
 Bansal J, 220
 Barditch P, 346
 Barnes W, 279
 Bassa AGH, 164
 Bauer HM, 274
 Becker TM, 286
 Beebe JL, 140
 Benes S, 227
 Bergeron MG, 314
 Black JR, 262
 Bolan G, 14
 Botcherby M, 21
 Bottles K, 121
 Boyer R, 100
 Bradet R, 100
 Bramdev A, 164
 Bratos MA, 257
 Brinton LA, 279
 Brock S, 36
 Brown JE, 96
 Brown RC, 96
 Brunham RC, 168
 Bucquet D, 51
 Budd J, 89
- C**
- Cadell DM, 274
 Callahan JD, 220
 Castriciano S, 301
 Castro I, 314
 Cates W Jr, 174
- Cathrine V, 61
 Catoe KE, 77
 Catotti DN, 77
 Chamberland S, 314
 Cheang M, 168
 Chernesky MA, 152, 301
 Choong J, 248
 Clarke P, 77
 Cloud GA, 45
 Constantine NT, 220
 Copeland C, 279
 Corey L, 230
 Covino JM, 227, 262
 Cross E, 36
 Cuervo M, 257
 Cummings MC, 227, 262
- D**
- Dahlöf LG, 10
 Dalessio J, 230
 Dangor Y, 5
 Daniell FD, 294
 Danielsson D, 143
 Dan M, 158
 Darougar S, 61
 Davis CH, 248
 Davis JP, 28
 Debby A, 158
 de la Maza LM, 352
 DiGiorgio-Haag L, 307
 Dines RJ, 61
 Douglas JM Jr, 290
 Dowda H, 334
 Draft K, 227
 Dragavon J, 230
 Duval B, 100
- E**
- Eiros JM, 257
 Ekstrand M, 307
 Epp J, 279
 Ernst AA, 66
- F**
- Finelli L, 89
 Forslin L, 143
 Fortin C, 100
- G**
- Gamble WB Jr, 334
 Garnett G, 168
- Garnett GP, 105, 181
 Gee L, 307
 Gerikalmaz O, 236
 Gill MJ, 329
 Glass AG, 274
 Godin G, 100
 Gravitt P, 279
 Greer CE, 286
 Groves D, 152
 Gunn RA, 334
 Gutiérrez-Rodríguez MP, 257
 Gutmann J, 137
 Gutman R, 158
- H**
- Handsfield HH, 237, 269, 290
 Hanna N, 21
 Hart G, 126
 Hawkins RE, 294
 Hayes C, 36
 Hay PE, 1
 Heaton CG, 70
 Hearst N, 14
 Hildesheim A, 274, 279
 Hildeshiem A, 286
 Hillman RJ, 21
 Hilton JF, 307
 Hippeläinen M, 321
 Holmes KK, 41, 214, 230
 Hook EW III, 269
 Hoosen AA, 164, 265
 Hörting-Müller I, 243
 Hounsai A, 100
 Hunt WC, 286
 Hyams KC, 36, 294
- I**
- Ison C, 105
 Ison CA, 329
- J**
- Jang D, 152, 301
 Johansson E, 143
 Jones JL, 334
 Jones RB, 269
 Jones S, 279
 Joyce CF, 105
 Jutto P, 334
- K**
- Kallings I, 338
 Kamwendo F, 143
- Katz A, 158
 Kegeles SM, 14
 Keogh J, 307
 Kirby J, 118
 Knight ST, 248
 Kopp W, 243
 Koskela H, 321
 Koutsky LA, 230
 Krantz I, 10
 Krogwold RA, 36
 Kurman RJ, 274, 279
- L**
- Lampe M, 214
 Landers DV, 121
 Larroque B, 51
 Lee FK, 230
 Legault J, 198
 Lindan C, 14
 Lind I, 338
 Ludka D, 28
 Luger A, 110
 Luinstra K, 301
 Luinstra KE, 152
- M**
- Mahnès G, 100
 Mahoney MC, 209
 Mahony J, 301
 Mahony JB, 152
 Malone JD, 294
 Manos MM, 274, 279, 286
 Marsiglia VC, 220
 Martin DH, 66
 Martín-Rodríguez JF, 257
 McCormack WM, 227, 262, 269
 McCusker J, 81
 McKenzie P, 1
 McLaughlin CC, 209
 McMaster J, 168
 Meheus A, 194
 Mercer L, 137
 Messeri P, 70
 Messiah A, 51
 Mettetal J-F, 51
 Metzger BB, 209
 Meyer P, 334
 Michalek AM, 209
 Mogabgab WJ, 269
 Moi H, 143
 Moodley J, 164
 Morrison DM, 352

Morris RE, 198
Morse S, 353
Mosquera C, 147
Moss TR, 61
Mulchahey K, 45
Murphy DP, 209

N

Nadeau D, 100
Nahmias AJ, 230
Nathan M, 61
Ndoye I, 194
Nerad S, 243
Newhall J, 353
Noegel R, 118
Nutter C, 353

O

Oh MK, 45
Omar MAK, 265
Orduña A, 257
Orduña Prieto E, 257
Ortiz de Lejarazu R, 257

P

Palacio V, 147
Parmenter CA, 286
Pass MA, 45
Pass RF, 45
Patton DL, 214
Peer AKC, 265

Persson G, 10
Pfister J, 28
Pickard L, 152, 301
Piot P, 194
Potter LB, 201
Pulkkinen J, 321

R

Radebe F, 5
Rand S, 346
Raulston JE, 248
Rau MP, 140
Reimann K, 338
Renton A, 105
Rodríguez-Torres A, 257
Rompalo AM, 346
Rosenberg MJ, 41
Rouzioux C, 51
Rush BB, 274
Ryatt BK, 21

S

Saarikoski S, 321
Sampedro A, 147
Samra Z, 158
Schachter J, 121, 239, 307
Schiffman MH, 274, 279
Schrader M, 118
Schramm N, 248
Scott DR, 274
Seedat MA, 265
Sellors J, 301

Sellors JW, 152
Serour F, 192
Shafer M-A, 307
Shalwitz J, 307
Shangold GA, 137
Shangold MM, 137
Sharp TW, 294
Shoupe D, 137
Smith BL, 227
Soper DE, 137
Spitalny KC, 89
Stamm WE, 214
Stary A, 243
Stevens CE, 230
Stoddard AM, 81
Sung ML, 121
Syrjänen K, 321
Syrjänen S, 321

T

Taylor-Robinson D, 1, 21
Tchabo J-G, 279
Tekki N, 329
Teodorowicz L, 243
Thomas BJ, 1

V

van den Ende J, 265
Van De Velden L, 194
Van Dyck E, 194
Vaughn ML, 28

Vazquez S, 147
Velasco J, 147
Verdon MS, 290

W

Wade AA, 344
Walzman M, 344
Wasserheit J, 118
Wasserman SS, 220
Weinstock HS, 14
Wendel GD Jr, 269
Wheeler CM, 286
Whitaker L, 105
Wiggins SD, 290
Wignall FS, 36
Wolner-Hanssen P, 214
Wong K, 214
Woodland RM, 61
World Health Organization
Working Group on Virucides,
41
Wyrick PB, 248

Z

Zahel B, 243
Zakut H, 158
Zapka JG, 81
Zeng W, 214
Zenilman JM, 346
Zhang X, 220
Zorn M, 81
Zwickl B, 262

INDEX OF SUBJECTS

A

Adolescents

female

isolated asymptomatic urethral *C. trachomatis* infection in, 198
pregnant, *C. trachomatis* infection in, 45
male, drug use and sexual behavior in, 307

Africa

female granuloma inguinale in, 164
intravaginal foreign substance use in, 96
sub-Saharan, chlamydial infection in, 168

AIDS. See under Human immunodeficiency virus

American Social Health Association (ASHA)

funding efforts of, 59, 240, 299
status report of, 179, 240, 299

Amies' transport medium, for *H. ducreyi*, 5

Ampicillin/sulbactam, for syphilis, 237 (letter)

Anal human papillomavirus infection, cytologic diagnosis vs. DNA hybridization studies for, 147

Anal intercourse. See Sexual behavior, high-risk

Anogenital warts. See Condylomata acuminata

Antibiotic resistance, of *Neisseria gonorrhoeae* in Nicaragua, 314

tetM determinant detection for, 329

Antibiotics. See also specific agents

anti-inflammatory drugs with, for chlamydial salpingitis, 121

Antibodies, to nongenital chlamydia, impact of on *C. trachomatis* serology tests, 61

Antifungal therapy, empiric, for vaginal infections in diabetics, 265

Anti-inflammatory drugs, for chlamydial salpingitis, infertility and, 121

ASHA. See American Social Health Association (ASHA)

B

Bacterial vaginosis, ofloxacin and metronidazole for, 262

C

Cefixime, low-dose, for gonorrhea, 290

Cefotaxime, for gonorrhea, 269

Ceftriaxone, for gonorrhea, 227, 269

Chlamydia spp., nongenital, antibodies to, impact of on *C. trachomatis* serology tests, 61*Chlamydia trachomatis*

Chlamydiazyme test for, false-positive results of, gender and genital specimen type and, 301

detection of, in males, 1

as main cause of pelvic inflammatory disease, 158

serology tests for, impact of *C. pneumoniae* and *C. psittaci* on, 61

Syva enzyme immunoassay grey zone specimens of, confirmatory testing of, 140

- Chlamydia trachomatis* infection
 decreased prevalence of, 28
 isolated urethral asymptomatic, in adolescent girls, 198
 in male partners of women with acute pelvic inflammatory disease, 143
 pathogenesis of, in vitro human epithelial cell culture for, 249
 in sub-Saharan Africa, 164
 in young pregnant teenagers, 45
- Chlamydia trachomatis* salpingitis
 addition of anti-inflammatory drugs to antimicrobial therapy for, infertility and, 121
 pathogenesis of, spermatozoa and, 214
- Chlamydiazyme test, false-positive results of, gender and genital specimen type and, 301
- Cocaine abuse. *See also* Drug abuse
 condom use in, effect of AIDS education on, 81
 high-risk sexual activity in. *See* Sexual behavior, high-risk
 syphilis incidence and, 66, 89
- Columbian theory, of origin of syphilis, 110
- Condom, female, in vaginal trichomoniasis prevention, 137
- Condom use
 before and after AIDS education, in drug abusers, 81
 in high-risk heterosexual population, 14
 sexual behavior and, in never-married women, 201
- Condylomata acuminata
 cryotherapy vs. trichloroacetic acid for, 344
 cytologic diagnosis vs. DNA hybridization studies for, 147
 human papillomavirus DNA in, in males, 21
 physical and psychological effects of, in females, 5
- Contact tracing, for gonococcal infections, 181
- Contraception
 sexually transmitted diseases and, 174
- Crack cocaine. *See* Cocaine; Drug abuse
- Cryotherapy, for condylomata acuminata, vs. trichloroacetic acid, 344
- Cytomegalovirus infection, heterosexual transmission of, 36

D

- Diabetes mellitus, vaginal infections in, empiric antifungal therapy for, 265
- DNA, human papillomavirus, in urogenital tract of men with anogenital warts, 21
- DNA hybridization studies, vs. cytologic diagnosis, for anal human papillomavirus infection, 147
- DNA probe assay, vs. culture, for *N. gonorrhoeae* detection, 243
- Doxycycline, for early latent syphilis, asymptomatic neurosyphilis after, 346
- Drug abuse
 condom use in, effect of AIDS education on, 81
 high-risk sexual behavior and. *See also* Sexual behavior, high-risk
 in male adolescents, 307
 syphilis incidence and, 66, 89
- Drug resistance, of *Neisseria gonorrhoeae*
 in Nicaragua, 314
tetM determinant detection for, 329
- Drug therapy. *See* Antibiotics; Antifungal therapy; Anti-inflammatory drugs
- Dry sex, intravaginal substances for, in Zaire, 96

E

- Education
 for condom use, in drug abusers, 70, 81
 for safe sex practices
 effectiveness of, 51
 video instruction for, 70

- Emotional aspects
 of anogenital warts, in females, 5
 of herpes simplex virus infection, 77
- Enoxacin, for gonorrhea, 227

F

- Family planning
 sexually transmitted diseases and, 174
- Female condom, in vaginal trichomoniasis prevention, 137
- Finland, human papillomavirus infection in, prevalence of and risk factors for, in healthy males, 321
- Fluorescent antibody test, for *C. trachomatis* Syva enzyme immunoassay grey zone specimens, 140
- Foreign substances, intravaginal, in Zairian women, 96

G

- Genital herpes, psychosocial aspects of, 77
- Genital warts. *See* Condylomata acuminata
- Gonococcal infections, epidemiology of, contact tracing and, 181
- Gonorrhea. *See also* *Neisseria gonorrhoeae*
 ampicillin/sulbactam for, 237 (letter)
 cefotaxime and ceftriaxone for, 269
 enoxacin and ceftriaxone for, 227
 low-dose cefixime for, 290
 in male partners of women with acute pelvic inflammatory disease, 143
- Granuloma inguinale, in women, 164
- Greenland, epidemiology of non-penicillinase-producing *N. gonorrhoeae* isolates in, 338

H

- Haemophilus ducreyi*, transport media for, 5
- Health teaching
 for condom use, for drug abusers, 70, 81
 for safe sex practices
 effectiveness of, 51
 video instruction for, 70
- Hepatitis B and C
 heterosexual transmission of, 36
 with sexually transmitted diseases, in clinic and emergency room populations, 220
- Hepatitis B transmission, syphilis and, in female prostitutes, 257
- Herpes simplex virus infection, psychosocial aspects of, 77
- Herpes simplex virus type 2, seroprevalence of, underestimation of by microneutralization assay, 230
- High-risk behavior. *See* Drug abuse; Sexual behavior, high-risk
- Homosexuals, HIV infection in, risk factors for in "safer sex" era, 51
- Human immunodeficiency virus antibody, in clinic patients refusing and accepting testing, 334
- Human immunodeficiency virus infection
 antecedent hepatitis B or C and, 220
 homosexually acquired, risk factors for in "safer sex" era, 51
 virucides in prevention of, 41
- Human papillomavirus DNA, in urogenital tract of men with anogenital warts, 21
- Human papillomavirus infection
 anal, cytologic diagnosis vs. DNA hybridization studies for, 147
 anogenital warts in. *See* Condylomata acuminata
 prevalence and risk factors for, in healthy Finnish males, 321
 risk factors for
 in cytologically normal population, 286

- in high-risk population, 279
- in low-risk population, 274
- Human T-cell lymphotropic virus infection, antecedent hepatitis B or C and, 220

I

- Infertility, chlamydial salpingitis and, 121
- in sub-Saharan Africa, 168
- Intercourse. *See* Sexual behavior

L

- Leukocyte esterase urine strip, in *C. trachomatis* screening, in asymptomatic males, 152

M

- Media, transport, for *H. ducreyi*, 5
- Metronidazole, for bacterial vaginosis, 262
- Microneutralization assay, underestimation of HSV-2 seroprevalence by, 230
- Military personnel
 - heterosexual transmission of viral hepatitis and cytomegalovirus infection in, 36
 - risk factors for sexually transmitted diseases in, 294

N

- Neisseria gonorrhoeae*
 - DNA probe test vs. culture for, 243
 - infection with. *See* Gonorrhea
 - multiresistant strains of, in Nicaragua, 314
 - non-penicillinase-producing, epidemiology of in Greenland, 338
 - persistence of multiple serovars of, 105
 - tefM* determinant in, detection of, 329
- Neurosyphilis, asymptomatic, after doxycycline for early latent syphilis, 346

O

- Ofloxacin, for bacterial vaginosis, 262

P

- Popular pearly penile pearls, 192
- Patient education
 - condom use and, in drug abusers, 70, 81
 - for safe sex practices
 - effectiveness of, 51
 - video instruction for, 70
- Pelvic inflammatory disease
 - etiology of, 158
 - gonorrhea, genital chlamydial infection, and nonspecific urethritis in male partners and, 143
- Penis, artificial nodules in, 192

- Pregnancy
 - adolescent, *C. trachomatis* infection and, 45
- Prostitutes
 - hepatitis B transmission in, syphilis and, 257
 - Turkish, syphilis in, 236 (letter)
- Psychosocial aspects
 - of anogenital warts, in females, 5
 - of herpes simplex virus infection, 77

S

- Safe sex education
 - condom use and, in drug abusers, 70, 81
 - effectiveness of, 51
 - video instruction in, 70
- Salpingitis, chlamydial. *See also Chlamydia trachomatis* infection
 - addition of anti-inflammatory drugs to antimicrobial therapy for, infertility and, 121
 - spermatozoa in pathogenesis of, 214
 - in sub-Saharan Africa, 168
- Screening. *See also specific tests*
 - for *C. trachomatis*
 - in asymptomatic males, leukocyte esterase urine strip for, 152
 - Chlamydiazyme test for, false-positive results in, 301
 - impact of *C. pneumoniae* and *C. psittaci* on, 61
 - in males, 1
 - Syva enzyme immunoassay grey zone specimens in, confirmatory testing of, 140
 - microneutralization assay for, underestimation of HSV-2 prevalence by, 230
 - for syphilis, rapid plasma reagin teardrop card test for, 194
- Sexual behavior
 - condom use and, in never-married women, 201
 - high-risk
 - chlamydial infection and, in pregnant adolescents, 45
 - condom use and, 14
 - drug use and, in high-risk male adolescents, 307
 - educational interventions for, 51, 70, 81
 - HIV infection and, safe sex education and, 51
 - syphilis and, 66, 89
 - intravaginal substance use and, in Zaire, 96
- Sexually transmitted diseases
 - accelerated prevention campaign for, 118
 - with blood-borne infections, in clinic and emergency room populations, 221
 - family planning and, 174
 - intention to seek prompt care for, in college students, 100
 - prevention of, education for, 51, 70, 81
 - risk profiles and epidemiologic interrelationships of, 126
- South Africa, female granuloma inguinale in, 164
- Spermatozoa, in *C. trachomatis* infection pathogenesis, 214
- Spermicides, in HIV infection prevention, 41
- Sulbactam. *See* Ampicillin/sulbactam
- Syphilis
 - antecedent, mortality patterns and, 209
 - in cocaine abusers, 66, 89
 - early
 - latent, doxycycline for, asymptomatic neurosyphilis after, 346
 - risk factors for, 89
 - hepatitis B transmission and, in female prostitutes, 257
 - origins of, Columbian theory of, 110
 - rapid plasma reagin teardrop card test for, for field screening, 194
 - in Turkish prostitutes, 236 (letter)
- Syva direct fluorescent antibody test, for *C. trachomatis* grey zone specimens, 140

T

- Teenagers. *See* Adolescents
tetM determinant, in *N. gonorrhoeae*, detection of, 329
Tetracycline-resistant *Neisseria gonorrhoeae*, *tetM* determinant in, detection of, 329
Transport media, for *H. ducreyi*, 5
Trichloroacetic acid, for condylomata acuminata, vs. cryotherapy, 344
Trichomoniasis, prevention of, by female condom, 137
Turkish prostitutes, syphilis in, 236 (letter)

U

- Urethritis
 chlamydial. *See also* *Chlamydia trachomatis* infection
 asymptomatic, in adolescent girls, 198
 leukocyte esterase urine strip screening for, 152
 nonspecific, in male partners of women with acute pelvic inflammatory disease, 143
Urine specimen, for *C. trachomatis* detection, in males, 1
Urine strip, leukocyte esterase, in *C. trachomatis* screening, in asymptomatic males, 152

V

- Vagina, foreign substance insertion in, in Zaire, 96
Vaginal infections
 in diabetics, empiric antifungal therapy for, 265
 ofloxacin and metronidazole for, 262
Vaginal spermicides, in HIV infection prevention, 41
Vaginal trichomoniasis, prevention of, by female condom, 137
Video instruction, for safe sex practices, 70
Viral hepatitis
 heterosexual transmission of, 36
 with sexually transmitted diseases, in clinic and emergency room populations, 220
 syphilis and, in female prostitutes, 257
Virucides, in HIV infection prevention, 41

W

- Warts, anogenital. *See* Condylomata acuminata

Z

- Zaire, intravaginal substance use in, 96

